Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR

• Main Authors: Aleksandar Jovanovski, Jessica Petiti, Emilia Giugliano, Enrico Marco Gottardi, Giuseppe Saglio, Daniela Cilloni, Carmen Fava
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Cancers
• Subjects: BCR-ABL1; Chronic myeloid leukemia; molecular monitoring; international scale; conversion factor; MMR
• Online Access: https://www.mdpi.com/2072-6694/12/11/3287

The introduction of tyrosine kinase inhibitors in 2001 as a targeted anticancer therapy has significantly improved the quality of life and survival of patients with chronic myeloid leukemia. At the same time, with the introduction of tyrosine kinase inhibitors, the need for precise monitoring of the molecular response to therapy has emerged. Starting with a qualitative polymerase chain reaction, followed by the introduction of a quantitative polymerase chain reaction to determine the exact quantity of the transcript of interest-p210 BCR-ABL1, molecular monitoring in patients with chronic myeloid leukemia was internationally standardized. This enabled precise monitoring of the therapeutic response, unification of therapeutic protocols, and comparison of results between different laboratories. This review aims to summarize the steps in the diagnosis and molecular monitoring of p210 BCR-ABL1, as well as to consider the possible future application of a more sophisticated method such as digital polymerase chain reaction.